The randomised, double-blind, placebo-controlled TULIP 2 trial belongs to the rare phase 3 trials in which a biologic, in this case the type 1 interferon blocker anifrolumab, succeeds in meeting its primary endpoint, a composite lupus assessment response .
Anifrolumab is a human monoclonal antibody that binds the type 1 interferon receptor subunit 1. Type 1 interferons play a key role in the pathogenesis of systemic lupus erythematosus (SLE), as these cytokines are involved in the inflammatory pathways . Between 60% and 80% of adults with SLE have an increased type 1 interferon gene signature, which has been shown to correlate with disease activity [3,4]. Therefore, type 1 interferons are an interesting target for the therapy of SLE. In the TULIP 2 study, 180 patients with moderate-to-severe SLE were randomly assigned to receive anifrolumab (300 mg intravenously) or placebo every 4 weeks for 48 weeks. The primary endpoint of the trial was a differenc...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Lowest Risk of Infection after Therapy with an IL-12/IL-23 Blocker Next Article
Letter from the Editor »
Table of Contents: ACR 2019
Spotlight on Rheumatoid Arthritis
What is Hot in Systemic Lupus Erythematosus
Spondyloarthritis – the Beat Goes On
Osteoarthritis – State-of-the-Art
Reproductive Issues in Rheumatic Disease
Vasculitis – Novel Treatment Modalities
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.